In AD, it uncovered 3 molecular subtypes [104] and led to the development of a blood RNA test that distinguishes AD from other dementias before symptom onset [105,106], also highlighting the downregulation of NeuroD6 as a potential biomarker [107]. This evidence concerns the gene NEUROD6 and Alzheimer disease.